<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333499</url>
  </required_header>
  <id_info>
    <org_study_id>zsyy_xhs2017-10</org_study_id>
    <nct_id>NCT03333499</nct_id>
  </id_info>
  <brief_title>the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure</brief_title>
  <official_title>the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dalian University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators set out to evaluate the effects of the traditional Chinese medicinal
      mixture under the brand name YangXinShi (YXS) on the prognosis in patients with chronic heart
      failure when it is combined with the optimal combination drug treatment of heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in EQ-5D Questionnaire</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>health status measured in therms of five dimensions with the 5-level scale from 1-5, corresponding to having no problems and having extreme problems</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in EQ-VAS</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>visual analogue scale (VAS) of EQ-5D Questionnaire scaled from 0-100, corresponding to the worse and the best health imagined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in disease specific quality of life</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>assessment of disease-related QoL using Kansas City Cardiomyopathy Questionnaire (KCCQ-12) with 7 heart failure domains. Scores of each domain are scaled from 0-100, with 0 corresponding to the worst, 100 the best status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in heart rate variability</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>assessed by Holter monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular end-systolic diameters (in millimeters)</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>assessed by echocardiographic examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular end-diastolic diameters (in millimeters)</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>assessed by echocardiographic examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular ejection fraction (in percentage)</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>assessed by echocardiographic examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in exercise tolerance</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>assessed by the distance (in meters) walked on 6-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in metabolic equivalents (METs)</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>measured as (volume of O2 (ml) consumption/kg/min) / (3.5 ml VO2/kg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (in pg/ml)</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>assessed by blood tests</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YanXinShi placebo pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YanXinShi group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YanXinShi pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trimetazidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trimetazidine pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YangXinShi and Trimetazidine group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>YanXinShi and Trimetazidine pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YanXinShi placebo pills</intervention_name>
    <description>participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure</description>
    <arm_group_label>the control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YanXinShi pills</intervention_name>
    <description>participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure</description>
    <arm_group_label>YanXinShi group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine pills</intervention_name>
    <description>participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure</description>
    <arm_group_label>Trimetazidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YanXinShi and Trimetazidine pills</intervention_name>
    <description>participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure</description>
    <arm_group_label>YangXinShi and Trimetazidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients newly diagnosed with heart failure or have been diagnosed with chronic heart
             failure

          -  patients classified as NYHA II-IV (New York Heart Association)

        Exclusion Criteria:

          -  with severe liver or renal dysfunction

          -  with severe systematic conditions such as infection, malignant hypertension etc.

          -  hemodynamic instability (arrhythmia, acute cardiac infarction, aortic dissection etc.)

          -  not cooperating due to psychomotor deficiency, or with contraindications for exercise
             testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>qin yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>affiliated Zhongshan hospital of Dalian university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>haoren wang, M.D., M.S.</last_name>
    <phone>08641162893507</phone>
    <email>haoren_wang@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Cardiology, Affiliated Zhongshan hospital of Dalian University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qin yu, M.D., Ph.D.</last_name>
      <phone>08641162887018</phone>
      <email>yuqin@dlu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 26, 2017</last_update_submitted>
  <last_update_submitted_qc>November 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>age, gender, NYHA classification</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

